BioPharma Dive November 7, 2024
Ned Pagliarulo and Ben Fidler

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change at the FTC could lower M&A scrutiny.

Donald Trump’s victory in the U.S. presidential election Tuesday means change is coming for federal health agencies and the industries they regulate. It’s just not quite clear yet how dramatic that change might be.

Trump has pledged to “make America healthy again” and, in embracing Robert F. Kennedy Jr., a well-known critic of vaccines and pharmaceutical companies, has signaled such a campaign could feature unorthodox or disruptive ideas.

“I’m going to let him go wild on health,” Trump said in a campaign speech in New York last month. “I’m going to let him...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, FDA, Govt Agencies, Pharma / Biotech
Congressional spending plan: What’s in it for healthcare, and what isn’t
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Another House bill aims to protect against hospital cyberattacks
A health care earthquake in Congress

Share This Article